Product Description
Dicloxacillin is an oral, second generation penicillin antibiotic that is used to treat bacterial infections caused by penicillinase-resistant staphylococci. Dicloxacillin has been linked to rare instances of clinically apparent, idiosyncratic liver injury. Dicloxacillin is a broad-spectrum, semi-synthetic, beta-lactam, penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Dicloxacillin binds to penicillin binding proteins (PBP) located on the inner membrane of the bacterial cell wall. It also inhibits the cross-linkage of peptidoglycan, a critical component of bacterial cell walls. This leads to the inhibition of bacterial cell wall synthesis and eventually causes cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dicloxacillin)
Mechanisms of Action: PBP Antagonist,Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Brazil | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | Germany | Hong Kong | Iceland | India | Italy | Mexico | New Zealand | Norway | Pakistan | Peru | Portugal | Sweden | Taiwan | Thailand | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Thomas Benfield
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Community-Acquired Infections|Soft Tissue Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20132346 | P1 |
Recruiting |
Soft Tissue Infections|Community-Acquired Infections |
2014-01-25 |